Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 27;18:81. doi: 10.1186/s12964-020-00588-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 9 — PERK inhibitor blocks high glucose-induced neuronal apoptosis through inhibiting ER stress and enhancing CREB activity. a Cell viability of SH-SY5Y cells under high glucose with different concentrations of GSK2356157; b-d Western blotting and quantitative analysis of p-PERK and p-eIF2α expressions in SH-SY5Y cells under high glucose with or without different concentrations of GSK2356157; e-k Western blotting and quantitative analysis of p-PERK, p-eIF2α, BDNF, p-CREB (S133), PSD95, synaptophysin and Cleaved-Caspase 3 expressions in SH-SY5Y cells under high glucose treating with GSK or FGF1. GSK: GSK2356157. *p < 0.05 vs. the other two groups, n = 3. j A Schematic showing FGF1 ameliorates diabetes-induced cognitive dysfunction